Occasional Paper

From Office of Health Economics
Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).

Access Statistics for this working paper series.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

001561: Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?: Adrian Towse
000332: Costs and Benefits of Regulating New Product Development in the UK Pharmaceutical Industry: Keith Hartley;Alan Maynard
000322: Price Comparisons of Identical Products in Japan, the United States and Europe: W. Duncan Reekie
000217: Enhancing the Benefits from Biomedical and Health Research Spillovers: Office of Health Economics
000216: New Drugs to Tackle Antimicrobial Resistance: EU Policy Options: Adrian Towse
000191: Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?: Patricia Danzon;Martina Garau;Adrian Towse
000171: Critical Review of the Quality and Competition Measures and Identification Strategies Used in Health Care Studies: Arik Mordoh
000167: The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?: Adrian Towse
000106: Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold: Adrian Towse;Paul Barnsley;Sarah Karlsberg-Schaffer;Jon Sussex
000076: The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness: Jorge Mestre-Ferrandiz;Patricia Deverka;Michele Pistollato;Emily Rosenberg